UIHistories Project: A History of the University of Illinois by Kalev Leetaru
N A V I G A T I O N D I G I T A L L I B R A R Y
Bookmark and Share



Repository: UIHistories Project: Dedication - Turburculosus Research [PAGE 2]

Caption: Dedication - Turburculosus Research
This is a reduced-resolution page image for fast online browsing.


Jump to Page:
< Previous Page [Displaying Page 2 of 4] Next Page >
[VIEW ALL PAGE THUMBNAILS]




EXTRACTED TEXT FROM PAGE:



A STEP FORWARD IN PREVENTIVE MEDICINE

BCG, the Bacillus of Calmette and Guerin, is an anti-tuberculosis vaccine which was developed in France. European claims for this simple tuberculosis control measure attracted the attention of Chicago doctors more than 15 years ago. A strain of the bacillus was brought to Chicago in 1935 and intensive research was started here to prove the value of the vaccine in United States health programs. The investigation, conducted in Chicago by the cooperative efforts of the Municipal Tuberculosis Sanatorium, the University of Illinois, the Mayor's Committee, and Research Foundation, under the leadership of Dr. Frederick Tice and the scientific supervision of Dr. Sol R. Rosenthal, has yielded the best controlled scientific data demonstrating the favorable effects of BCG vaccination. The techniques for vaccination developed in the Chicago laboratory, like some of the vaccine produced there, are being used throughout the world in the fight to control tuberculosis. In the past several years, millions of people have been vaccinated under the auspices of the World Health Organization, the United Nations Children Organization and other agencies doing rehabilitation work in Europe and Asia. In Russia the law requires that all babies be vaccinated at birth. Norwegian law can compel BCG vaccination for certain age groups. Almost every area of the globe is using BCG to supplement other tuberculosis control methods. The National Tuberculosis Association, the United States Public Health Service, the Illinois State Medical Society, and other professional groups have recommended large-scale testing of the vaccine in this country to determine its place in the health programs of the immediate future. Further laboratory and clinical research in the application and production of the vaccine will be carried on in this new building under a joint program of the University of Illinois, the Municipal Tuberculosis Sanatorium, the Tuberculosis Institute of Chicago and Cook County, and Research Foundation.